Malaria: Africa’s First Long-Acting Injectable Trial Begins In Rwanda

Africa’s first-ever Phase 1b clinical trial of a long-acting injectable drug for malaria prevention has commenced in Rwanda, marking a significant step towards developing new tools to combat the disease.
Medicines for Malaria Venture (MMV), a non-profit organisation dedicated to developing antimalarial medicines, and Rinda Ubuzima, a Rwandan health research organisation, announced the launch of the trial of MMV371, a potential long-acting injectable (LAI) designed to provide extended protection against malaria.
Malaria: Zamfara Deputy Governor Hails Distribution Of 3.5m Mosquito Nets
Insecurity Hampering TB, HIV/AIDS, Malaria Services In Zamfara – Network
 
The trial is the fir...